At a glance
ClinicalIndex Comparison RecordN/ACompleted· 662 enrolled
Drug / intervention
Nepafenac 0.3% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pseudophakic Cystoid Macular Edema Prevention and Risk Factors; Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo
In Brief
A clinical study evaluating Nepafenac 0.3% and Saline Solution for Cystoid Macular Edema. Completed, enrolled 662 participants.
Detailed Summary
Prospective, randomized, double-masked, placebo-controlled clinical study to define the effective use of a topical non-steroidal anti-inflammatory drug added to topical steroid use after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular edema.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystoid Macular Edema
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
Primary CompletionJan 2017
First PostedJan 2017
TodayJul 2026
First PostedJan 20, 2017
Enrollment StartOct 1, 2013
Primary CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 9.5 years ago
Interventions
Nepafenac 0.3%drug
Saline Solutiondrug